PCSK9 and diabetes mellitus: However, mostof the previous studies were designed as direct meta-analyses, and none of themevaluated the relative effects of PCSK9 monoclonal antibodies and bempedoic acidon the secondary prevention of new-onset diabetes and cardiovascular events[25, 29, 30].